日前，启明创投投资企业、致力于通过精准蛋白质组学实现疾病早期检测的公司Alamar Biosciences（下称“Alamar”）宣布其全球化进程的最新进展：已在香港神经退行性疾病中心（“HKCeND”）安装了先进的超灵敏蛋白质组学平台——ARGO™ HT系统。这是其在亚太地区实现的首套装机，标志着Alarma正式落地亚太地区。
ARGO™ HT系统和NULISA™技术相结合，旨在通过前所未有的灵敏度和准确性，使科学家能够更好地检测和定量蛋白质，从而彻底革新生物标志物的发现过程。
HKCeND安装培训现场Alamar与HKCeND的合作将专注于揭示阿尔茨海默病和帕金森病等神经退行性疾病的分子机制和由此带来的新见解。ARGO HT™和NULISA™平台的部署将进一步增强HKCeND的研究团队识别新的生物标志物、加速药物开发，并改善患者的早期检测和个性化治疗策略的能力。
Alamar Biosciences创始人、董事长兼CEO罗宇龄博士表示：“将ARGO™ HT系统安装到亚太地区，是我们将突破性蛋白质组学解决方案带给全球研究者的愿景中的重要一步。我们很高兴能够为HKCeND充满活力的科学社区做出贡献，并支持其在应对神经退行性疾病方面取得更多的突破性进展。”
香港神经退行性疾病中心主任叶玉如院士表示：“将ARGO™ HT系统及其支持的NULISA™技术整合到我们的研究基础设施中，是一项颠覆性的革新。这项技术将使得我们能够以此前无法想象的方式探索神经退行性疾病的蛋白质组学基础。”
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO™ HT Install at Hong Kong Center for Neurodegenerative Diseases
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease and a portfolio company of Qiming Venture Partners, announces its commercial presence in the Asia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sensitive proteomics platform, at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND).
The ARGO™ HT System along with the NULISA™ Platform are designed to revolutionize biomarker discovery by enabling researchers to detect and quantify proteins at unprecedented levels of sensitivity and accuracy.
The partnership with HKCeND will focus on unlocking new insights into the molecular mechanisms of neurodegenerative diseases such as Alzheimer's disease, and Parkinson's disease. The ARGO™ HT System and NULISA™ Platform deployments will empower HKCeND's researchers to identify novel biomarkers, accelerate drug development, and improve early detection and personalized treatment strategies for patients.
"Expansion of the ARGO™ HT installed base to the APAC region represents a significant step forward in our vision to bring transformative proteomics solutions to researchers worldwide," said Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. "We are excited to contribute to HKCeND's vibrant scientific community and support groundbreaking advancements in the fight against neurodegenerative diseases."
Prof. Nancy Ip, the Director of Hong Kong Center for Neurodegenerative Diseases (HKCeND), added, "The integration of the NULISA™ Technology enabled by the ARGO™ HT System into our research infrastructure is a game-changer. This technology will allow us to explore the proteomic underpinnings of neurodegenerative diseases in ways that were previously unimaginable."
（转自：启明创投）
发表评论